Open access peer-reviewed chapter

Vitamin D and Its Relationship with the Pathways Related to Thrombosis and Various Diseases

Written By

Syed Mohd, Swati Sharma, Aastha Mishra and Mohammad Zahid Ashraf

Submitted: December 11th, 2020 Reviewed: March 17th, 2021 Published: April 29th, 2021

DOI: 10.5772/intechopen.97299

Chapter metrics overview

623 Chapter Downloads

View Full Metrics


Vitamin D known for its vital role in diverse biological function such as calcium and phosphorus homeostasis, also exert an anticoagulant effect emphasizing its essential role in the thrombosis pathogenesis. Thrombosis is the formation and propagation of a blood clot or thrombus either in the arterial or the venous system resulting in several severe complications. Various studies have also reported the association of vitamin D deficiency with the increased incidences of thromboembolism. This may be in part due to its anticoagulant effects through upregulation of thrombomodulin, an anticoagulant glycoprotein, and downregulation of Tissue Factor, a critical coagulation factor. The protective effects of vitamin D and its receptor in endothelial cells may further explain some of the reported beneficial effects of vitamin D in the prevention or treatment of cardiovascular diseases. Additionally, the immunomodulatory role of vitamin D has been observed through its ability to alter the secretion of inflammatory cytokines that can induce a procoagulant milieu by multiple pathways. Therefore, it becomes pertinent to discuss the close link between vitamin D and human health and to improve our knowledge of the molecular pathways regulated or influenced by vitamin D and its associated metabolites.


  • vitamin D
  • vitamin D receptor
  • thrombosis
  • coagulation
  • immune response

1. Introduction

Vitamin D is a lipophilic, steroid hormone, obtained from various food sources as well as majorly synthesized by the body in the skin through exposure to ultraviolet irradiation [1, 2]. In nature, vitamin D exists in two forms, vitamin D2, and vitamin D3. 25-hydroxyvitamin D (25(OH)D) is the major circulatory form and 1,25-dihydroxyvitamin D (1,25(OH)2D) is the active form of vitamin D that exerts its activity by binding to and activating the nuclear vitamin D receptor (VDR), which is a ligand-inducible transcription factor [3]. Upon activation, VDR forms a heterodimer with the retinoid-X receptor (RXR) that interacts with particular DNA sequences in the promoter region of target genes called vitamin response elements (VDREs) [4]. Vitamin D exerts a diverse biological function such as cell proliferation, calcium and phosphorus homeostasis, and cell differentiation. Most of these actions are carried out by regulating the expression of target genes through VDR activation [3].

Vitamin D deficiency is a widespread condition, reportedly occurring in 30 to 60% of the general population worldwide [5, 6, 7]. Vitamin D is commonly known for its vital role in calcium homeostasis and bone mineralization. It is also crucial in the prevention of rickets during early age and osteomalacia during adult age [8, 9]. Increasing evidence from clinical reports, cross-sectional studies, and cell culture studies further indicate that vitamin D may exert an anticoagulant effect emphasizing an essential role of vitamin D metabolites in the pathogenesis of thrombosis [10, 11, 12]. VDR is expressed throughout the body including various immune cells such as macrophages, dendritic cells, and lymphocytes [13, 14, 15, 16, 17]. They are also expressed in the vascular endothelial cells [18], which are relevant to hemostasis.

Thrombosis is the formation of a blood clot within the intact vascular system. It can occur in both arterial and venous systems [19]. Rudolf Virchow, a German scientist, and physician proposed the three main factors that may predispose an individual to the development of thrombosis: stasis, endothelial dysfunction, and hypercoagulability. Apart from these three factors, the innate inflammatory system also has an intrinsic link with coagulation, whereby activation of the inflammatory system promotes thrombosis and vice versa [20, 21]. Interventional studies have shown vitamin D treatment enhances endothelial functions and reduces the production of pro-inflammatory cytokines [22, 23, 24]. Apart from this, the anti-thrombotic effect of vitamin D on the pro-thrombotic and anti-thrombotic components of the coagulation system has also been well defined [25, 26, 27]. In this chapter, we are defining the effect of vitamin D deficiency in the three most important parameters viz. coagulation, endothelial activation, and immune responses affecting the occurrence of thrombosis. This chapter will also discuss the clinical impact of Vitamin D in various diseases including COVID-19.


2. Vitamin D in coagulation

Vitamin D deficiency is defined based on the plasma levels of 25(OH)D. Individuals with plasma levels under 20 ng/mL are considered vitamin D deficient. Vitamin D deficiency is highly prevalent worldwide with approximately 30–50% incidences [28, 29, 30]. Several reports have established the significant association of vitamin D deficiency with the increased risk of various cardiovascular diseases (CVDs) and mortality [31, 32, 33]. Various studies have also reported the association of vitamin D deficiency with the increased incidences of thromboembolism [34, 35, 36]. As suggested by the studies, the underlying molecular mechanism for the antithrombotic potential of vitamin D includes up-regulation of thrombomodulin and downregulation of tissue factor (TF) [25, 36, 37]. Additionally, vitamin D upregulates and increases the level of anti-inflammatory cytokines like IL-10 [2438]. The expression profile of more than 200 genes involved in the regulation of cellular proliferation, differentiation, apoptosis, and angiogenesis is directly or indirectly regulated by vitamin D [39]. The experimental shreds of evidence obtained from cell culture studies depicted that biologically active form of vitamin D3 i.e., 1,25(OH)2D, and its synthetic analogs exerted the anticoagulant effects [40]. Koyama et al. have demonstrated in their experiments on human peripheral monocytes that 1,25(OH)2D exerted the anticoagulant effects by upregulating the expression of thrombomodulin, an anticoagulant glycoprotein, and downregulating the expression of TF, a critical coagulation factor [13]. 1,25 (OH)2D directly suppresses renin gene expression via a vitamin D-response (VDR) element that is present in the renin gene [41]. Different studies on mouse embryonic fibroblasts from VDR Knockout (VDRKO) mice asserted an increase in pro-fibrotic factors including nuclear factor kappa B, interleukin (IL)- 6, and TNF-α suggesting that 1,25 (OH)2D may have antifibrotic effect and hence modulates multiple signaling pathways, like the transforming growth factor-β/Smad signaling [42]. Experiments with VDRKO mice showed enhanced ADP-induced platelet aggregation, down-regulation of thrombomodulin and anti-thrombin, and upregulation of TF at mRNA level [43]. The VDR system has a physiological role in the maintenance of anti-thrombotic homeostasis as exacerbated multiorgan thrombus formation has been observed in VDRKO mice after lipopolysaccharide injection [43]. Recently, it has been documented that human platelets and megakaryocyte lineage also express VDR [44]. Hyppönen et al. documented that serum 25(OH)D level inversely associated with tPA antigen, fibrinogen, and D-dimer, suggesting a possible role for vitamin D3 status in determining thrombolytic profile [45]. It is well studied that inflammation can cause coagulation with high sensitivity C-reactive protein (hs-CRP) [46, 47]. A study comprising of 206 individuals reported significant inverse associations between 25(OH)D and PAI-1 and tPA antigen levels and between 1,25(OH)2D and tPA and hs-CRP levels [48].

However, because of the small number of clinical trials and heterogeneity, more studies need to be conducted to further define the haemostatic abnormalities seen in individuals with vitamin D3-deficiency, and to precisely define the potential benefits of vitamin D3 supplementation as a preventive measure for various CVDs.


3. Vitamin D in endothelium homeostasis

The pathogenesis of cardiovascular diseases is governed by endothelium homeostasis. The vascular endothelium is of mesodermal origin and is located at the confluence between blood and the underlying vascular tissues. It not only works as a barrier function but also exerts several vasoprotective roles, and is considered as the main regulator of blood vessel homeostasis. Due to its inherent capability to perceive humoral and hemodynamic stimuli [49], the endothelium is instrumental in local regulation of vascular tone and structure, regulation of migration and growth of VSMCs, and controlling the adhesion and extravasation of leukocytes [50, 51]. Destabilization and activation of the endothelium take place as a result of injury, hemodynamic alteration, response to inflammatory cytokines, as well as genetic disorders [52, 53]. Endothelial dysfunction is found in various conditions that adversely affect the cardiovascular system, including hypertension, diabetes mellitus, atherosclerosis, chronic renal failure, and Deep venous thrombosis (DVT) [54]. Endothelial cells (ECs) in a quiescent form exhibit an anti-coagulant, vasodilatory, and anti-adhesive property [55]. However, when activated they express pro-coagulant, vasoconstricting, and pro-adhesive properties [56]. Hemostasis is facilitated by an equilibrium of anticoagulant and procoagulant factors [56]. On one side of the hemostatic equilibrium, the ECs express anticoagulant factors such as thrombomodulin TM, tissue factor pathway inhibitor (TFPI), and tissue-type plasminogen activator (t-PA). On the other side, they express thrombin receptors, TF, plasminogen activator, and von Willebrand factor (vWF) [56].

The VDR has been identified in endothelium cells, and hydroxylation of 25(OH)D to 1,25(OH)2D also takes place in the endothelium [18, 57]. The expression of VDR and 1-alfa hydroxylase in the endothelium was found to be decreased with 25(OH)D deficiency [58]. In the vascular system, it has been recognized that vitamin D controls the proliferation of endothelial cells and vascular smooth muscle cells [59, 60]. Vitamin D up-regulates the production of nitric oxide (NO) in ECs [31], by increasing eNOS expression [61], which helps in reducing arterial stiffness [62]. Various randomized control trials (RCTs) have demonstrated an improvement in endothelial dysfunction in healthy individuals [23, 63, 64], as well as in patients [65, 66] and improvement of arterial stiffness with improved flow-mediated dilation (FMD) after vitamin D supplementation [67]. A study by Davide Carrara et al. showed restoration of normal vitamin D levels after prolonged supplementation with a high dose of cholecalciferol (50,000 IU/week orally for 8 weeks) is associated with inhibition of peripheral renin-angiotensin system and with an improvement of FMD in essential hypertensive patients with hypovitaminosis [68]. The 25(OH)D presumed to be an inactive sterol is also found to be a potent mediator of endothelial stability in a non-genomic manner at physiologically relevant levels [69].

1,25(OH)2D3 supplementation reduces oxidation stress, NF-kappa B activation, Intercellular Adhesion Molecule 1 (ICAM-1), and Monocyte chemoattractant protein-1 levels in the endothelium cells [70]. Vitamin D also downregulates platelet-activating factor (PAF) induced ICAM-1 expression in the ECs [71]. Another study observed a greater level of p65 subunit of NF-kB, and IL-6 in vitamin D deficient groups as compared to the vitamin D sufficient group [72]. Vitamin D has also been shown to inhibit activation of proinflammatory TF, NF-kB, and its downstream target, IL-6 [73], which is a pro-inflammatory cytokine in cultured vascular ECs [74] In addition, Vitamin D has been demonstrated to reverse Angiotensin II (Ang II) induced oxidative stress, a key mediator of endothelial dysfunction [75]. Ang II not only induces the production of ROS but also activates TF NF-kB, which further upregulates several cytokines such as TNF-alfa, IL-6, and adhesion molecules ICAM-1, Vascular cell adhesion molecule 1 (VCAM-1), and E-selectin prompting vascular injury [76]. In vivo, VDR knockdown leads to an increase in leukocytes-endothelial interaction associated with endothelial cell activation markers VCAM-1 and ICAM-1 in endothelial cells [77].

Given the recognized significance of endothelial function in the homeostasis of the cardiovascular system, the protective effects of VDR in endothelial cells may explain by some of the reported beneficial effects of vitamin D attributed to the prevention or curing of cardiovascular disease [78, 79]. Vitamin D therapy has been observed to be associated with improvement in endothelial function in ischemic heart disease (IHD) patients with vitamin D deficiency or insufficiency [80]. Further, in vitro supplementation of vitamin D improved endothelial progenitor cell ability in the formation of colonies in type 2 diabetes mellitus patients [81]. Cuenca et al. demonstrated that paricalcitol, a vitamin D substitute attenuates the endothelium damage induced by the chronic kidney disease in the thoracic aorta and directly mediates stability of endothelium in vitro by enhancing cell–cell interactions resembling a protective mechanism [82].


4. Inflammation and thrombosis

Thrombosis and inflammation are the two intrinsically interlinked processes. Inflammation can induce a procoagulant milieu by multiple pathways such as by causing an imbalance between procoagulant and anticoagulant characteristics of the endothelium that can lead to local stimulation of coagulation cascade. TNF-α, a pro-inflammatory cytokine that is a potent inducer of the immune defense mechanism and the first to be released at the site of infection promotes a pro-coagulant state by eliciting the production of TF on the endothelium [83] and suppressing the synthesis of the anticoagulant protein C [84], thereby stimulating fibrin formation. Inflammatory stimuli change the cellular program of the endothelium by expressing adhesion molecules such as p-selectin and E-selectin facilitating a transition toward a more procoagulant phenotype [85].

Other cells of the circulation are also customized by inflammatory molecules toward a pro-thrombotic state such as neutrophils and monocytes expression of TF [86, 87], which is upregulated upon inflammation. The role of sterile inflammation has also been demonstrated in the thrombosis by a direct association between nucleotide-binding domain, leucine-rich-containing family, pyrin domain containing 3 (NLRP3) inflammasome complex, and hypoxia-inducible factor-1 alpha in hypoxia-induced thrombosis associated with an increase in the relative expression of caspase-1, interleukin-1beta and IL-18 transcripts in the individuals with venous thrombosis [20]. In recent years, the role of vitamin D as a regulator of both innate and adaptive immune responses has become very clear [88]. Local synthesis of 1,25-(OH)2D at the site of inflammation can modulate the immune response in a paracrine manner [89]. 1,25(OH)2D binds to the nuclear VDR which has been found to be expressed in various cells of the immune system such as macrophages, activated T-cells, B-cells, Dendritic cells, and monocytes [90, 91].

The immunomodulatory role of vitamin D has been observed through its ability to alter the secretion of inflammatory cytokines [92, 93]. Additionally, multiple studies are suggesting an inverse association between vitamin D level and inflammatory cytokines such as TNF-α, IL-6, and CRP [16, 17, 18, 19, 20], which are correctable by vitamin D supplementation [94, 95, 96]. Furthermore, lower vitamin D levels have also been associated with an increase in the levels of cellular adhesion molecules such as VCAM and ICAM [97].

Moreover, an increased incidence of auto-immune disorders in higher latitudes has been reported, which could be attributed to low UV-radiation that reduces the ability to synthesize vitamin D [98, 99]. Elderly peoples usually tend to have Hypovitaminosis D [26], which has been associated with an increased risk for chronic diseases where inflammation plays an integral component [100, 101]. A study by EM Akbas et al. revealed an inverse association between Vitamin D levels and inflammation through Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) which are novel and inexpensive markers of inflammation. They found a significantly higher NLR and PLR in patients with lower 25(OH)D status [102].

Further, several cross-sectional studies have associated vitamin D levels and inflammation. Amer and Qayyam Studied 15,167 men and women aged 18 years and older [103]. They observed a negative association between vitamin D and inflammatory markers such as CRP and IL-6 in the vitamin D deficient groups (<25 nmol/L). This association was not observed in groups with insufficient and sufficient vitamin D status [104]. Bellia et al. examined the association of vitamin D and inflammatory markers in 137 morbidly obese individuals including both men and women. They also observed a significant inverse association between serum 25(OH)D levels and inflammatory markers like CRP, IL-6, and TNF-α [105]. A clinical trial by SS Bidar et al. observed a significant decrease in the systemic inflammatory markers including hsCRP, serum amyloid A, TNF-α, and IL-6 with the increase in circulating vitamin D after a daily intake of vitamin D fortified yogurt drink in the subjects with type 2 diabetes (T2D) [96]. However, in another clinical trial, Jorde et al. [106] observed no significant effects on hsCRP levels in the subjects randomly assigned to the therapy for 1 year with vitamin D3 40,000 IU per week, 20,000 IU per week, or placebo.


5. Clinical impact of vitamin D in various diseases

There is a close link between vitamin D and human health, vitamin D deficiency is widely associated with several diseased conditions by physicians and patients. The various diseases affected by vitamin D deficiency can be categorized as cardiovascular disease (hypertension, thrombosis), various cancers, autoimmune diseases like multiple sclerosis, rheumatoid arthritis, and metabolic syndromes like osteomalacia, diabetes, and muscle weakness (Figure 1).

Figure 1.

Reported Association of Vitamin D deficiency with various human disease.

Osteomalacia is a classical human manifestation associated with vitamin D deficiency. It is a clinical condition in which bone mineralization is hampered due to low concentrations of phosphorus and calcium in the extracellular fluid [107]. Vitamin D plays a crucial role in maintaining an adequate level of serum phosphorus and calcium. In the absence of vitamin D or its deficiency, only 10 to 15% of dietary calcium and 60% of phosphorus are absorbed in the human body [108, 109, 110]. With the advent of technologies, molecular biology has permitted a more detailed characterization of the effects of vitamin D deficiency, via working on the animals lacking the VDR and studying their phenotype. Subtle abnormalities in the immune and cardiovascular system have been defined in the global VDRKO mouse, but their relevance to human disease is still obscure [111]. Greater awareness of the high prevalence of vitamin D inadequacy and its associated abnormalities is required among researchers, clinicians, and patients. There has been a large number of trials concerning the effects of vitamin D on the management and prevention in the last two decades. The most studied diseases in this aspect have been discussed below:

5.1 Osteoporosis

The association between osteoporosis and vitamin D deficiency is well established especially in the elderly. Vitamin D deficiency has been linked with the significant suppression in intestinal Calcium absorption and the impairment of its balance, which causes low bone mineral content and density. Decreased bone mineral density (BMD) raises the risk of bone fractures, which contributes significantly to the hospitalization, morbidity, and mortality of elderlies [112113]. Several studies have demonstrated the efficacy of vitamin D as a preventive measure for fractures. Clinical trials recommending the use of 700 to 800 IU/d oral vitamin D with or without Ca supplementation reported a significant 26% decrease in the risk of sustaining a hip fracture and a significant 23% decrease in the risk of sustaining any non-vertebral fracture vs. placebo or Calcium alone [114].

5.2 Muscle weakness

One of the prominent features of vitamin D deficiency is muscle weakness. Several clinical data of patients with nonspecific muscle weakness, muscle aches, and pains have shown vitamin D inadequacy [115, 116]. It has been reported that skeletal muscle tissue contains VDR and needs vitamin D to attain maximum function [117]. Recent studies have associated the increased vitamin D levels with improved muscle performance, and thereby reduced incidences of fall and fracture. A 5-month randomized controlled trial study has exhibited a 72% reduction in the risk of falls as compared with the placebo group in elderly people in a nursing home receiving 800 IU of vitamin D2 plus calcium daily [118].

5.3 Hypertension

Hypertension affects the population globally. Increasing evidence in recent times suggests that vitamin D has a crucial role in regulating blood pressure. Animal studies indicate that 1,25-dihydroxy vitamin D inhibits renin expression in the juxtaglomerular apparatus and blocks the proliferation of vascular smooth muscle cells, which affects systemic blood pressure [119]. People taking oral supplementation of vitamin D were found to have reduced blood pressure. The exposure of skin to UVB rays, a major source of vitamin D formation, has been associated with lower blood pressure [120, 121, 122].

5.4 Multiple sclerosis

Multiple sclerosis (MS) is an auto-immune disease characterized by the attack of self- immune system on the myelin sheath which works as a nerve insulator. The transmission of nerve signals gets affected leading to disrupted communication between the body and brain.. There have been several reports claiming the increased frequency of MS in temperate climates than in the tropics [123, 124]. Furthermore, studies also suggest that there is a strong negative correlation between the short annual, winter hours and frequency of occurrence of MS [125, 126]. Hence, these studies could hypothesized that vitamin D synthesized during sun exposure exerted a protective effect [127, 128, 129]. In addition, There are few studies that indicated low or insufficient levels of vitamin D in MS patients [130, 131, 132].

5.5 Rickets

The re-arrival of worldwide vitamin D deficiency has led to the re-emergence of rickets. Low levels of vitamin D in breastfeeding mothers can, often, lead to deficiencies in their children. The recommended levels of vitamin D supplements are 400 IU/d for infants to avoid diseases such as rickets [8].

5.6 Cancer

Garland and Garland for the first time reported that vitamin D deficiency could be associated with a higher risk of colon cancer mortality. Recent studies have reported an increased risk of several cancers with vitamin D deficiency, suggesting that vitamin D deficiency may account for premature mortality from colon, breast, ovarian, and prostate cancer [133, 134, 135]. Vitamin D is a potent hormone and regulates cell growth. VDRs are expressed by various cells and get activated by 1,25(OH)2 D, inducing differentiation into normally functioning cells, and inhibiting proliferation, angiogenesis, invasiveness, and metastatic potential. Studies reveal that tumor models of lung, colon, kidney, breast, and prostate cancer, vitamin D showed activity against metastasis [136, 137, 138, 139, 140, 141]. These studies have also shown the immunomodulatory effect of Vitamin D. It has been reported that when elicited by an inappropriate and overly exuberant immune response, vitamin D acts in a paracrine manner and decreases T cell responsiveness via inhibition of cellular proliferation and reduced lymphokine production. Thus, vitamin D shows a beneficial effect as an immunosuppressant.

5.7 Diabetes

Vitamin D deficiency is known to inhibit pancreatic secretion and turnover of insulin, causing impaired glucose tolerance. An association was found between a low level of vitamin D and a high incidence of type 1 diabetes [142].

5.8 Tuberculosis

Tuberculosis (TB) is one of the global health problems causing 2 million deaths a year. It is estimated that approximately one-third of the global population carries latent TB infection, which poses potential health risks of reactivation in the future. Before the use of antibiotics to treat TB, high doses of vitamin D were widely used [143]. Cross-sectional studies indicated that patients with TB possess a decrease 25(OH)D levels in comparison with the control population.

5.9 Thrombosis

As discussed in previous sections, vitamin D can tackle thrombosis by influencing inflammatory pathways, coagulation factors, and endothelium homeostasis in a pleiotropic manner. Figure 2 illustrates a possible mechanism through which vitamin D might impart its protective role against the occurrence of thrombosis. Several clinical trials have also highlighted the anti-thrombotic actions of vitamin D. A study by TM Beer et al. involving 250 cancer patients for high dose calcitriol supplementation, a total of 13 thrombotic events were observed of which 11 occur placebo-treated and only 2 occur in high dose calcitriol-treated cancer patients [35]. Vitamin D has been found to inhibits in-vitro anti beta2GPI antibodies (purified from patients with antiphospholipid syndrome (APS)) induced TF expression indicating the association of vitamin D deficiency and decreased inhibition of TF expression and increased coagulation in APS [34]. M Blondon et al. investigated the role of oral supplementation of vitamin D3 in the placebo-controlled RCT in 36,282 postmenopausal women. Subjects were randomized to receive 1000 mg of calcium carbonate and 400 IU of vitamin D3 per day for an average period of 7 years and observed a reduced risk of idiopathic VTE in women randomized to calcium and vitamin D [144]. A 60% lower rate of VTE was observed in 769 renal transplant recipients after combined therapy with calcitriol 0.5ug/day, angiotensin-converting enzyme inhibitor (ACEi), and angiotensin receptor blocker (ARB) [145]. Another prospective study which included a cohort comprising of 40,000 women followed for a mean period of 11 years concluded a 30% lower risk of VTE in women with a habit of more active sun exposure [146]. Moreover, another study determined a 50% increased risk of VTE in winter, during which vitamin D status has been established to be the lowest as compared to another season [147].

Figure 2.

Possible mechanism of the protective role of vitamin D in the occurrence of thrombosis.

5.10 COVID-19

The COVID-19 pandemic has affected all of us globally. The lack of understanding of the mechanism of action of SARS-CoV2 virus has generated an overall interest in understanding the potential risk factors that may explain the mechanistic basis for disease propagation and control. The role of vitamin D has emerged in COVID-19 as well. The innate immune system forms the first line of defense against invading pathogens including viruses. 1,25(OH)2D enhances innate defense by inducing antimicrobial peptides like cathelicidin that result in the destruction and clearance of viral particles via several molecular mechanisms. It also helps in the recruitment of neutrophils, monocytes/macrophages, and dendritic cells for killing and clearance of viral particles, and initiation of the immune response. Further, the chronic activation of the innate immune system in COVID-19 infection results in a cytokine storm. It has been hypothesized that 1,25(OH)2D helps in curtailing this chronic innate immune response through various biological mechanisms such as downregulation of TLRs and direct inhibition of TNF/NFκB and IFNγ signaling pathways. 1,25(OH)2D, regulates adaptive immune response by limiting maturation of dendritic cells along with their ability to present antigen to T cells, thus limiting shifting of the T cell profile from proinflammatory Th1 and Th17 subsets to Th2 and Treg subsets. Thus, inhibits the pro-inflammatory processes. Although all these findings come from different studies with a variety of pathogens (virus/bacteria) the relevance of these protective actions of vitamin D on SARS-CoV-2 can merit further investigation [148]. In a recent study of hospitalized COVID-19 patients, vitamin D deficiency was reported in 75% of the overall cohort and in 85% of those who required ICU admission [149]. Also, a European study analysis of SARS-CoV-2 severity based on vitamin D status suggested that countries with the highest rate of vitamin D deficiency are associated with the highest rates of COVID-19 infection and mortality [150]. Therefore, vitamin D supplements as a part of standard nutrition in COVID-19 may provide certain clinical benefits though more research related to this subject is solicited [151].


6. Conclusion

Inadequacy or deficiency of vitamin D is a global problem. Though recent studies have established vitamin D as a key regulatory molecule in various physiological processes and have proposed it as a promising predictive/therapeutic tool still the close association of vitamin D with human health, and its deficiency in the body is not widely recognized as a health concern by both common man and physicians. The relation between vitamin D deficiency and the associated risk of various chronic and acute diseases is still obscure and requires intensive research efforts. In recent years, various studies have explored several non-calcemic consequences of vitamin D. There are reports that corelates lower doses of vitamin D with thrombosis and various cardiovascular diseases. Still, there is an impelling need to enhance our knowledge of the molecular pathways regulated/influenced via vitamin D and their effect on various organ systems including the cardiovascular system. This would require conducting large-scale intervention clinical trials to firmly establish the association of vitamin D status to cardiovascular health. Additionally, it is important to state that although deficiency of vitamin D is common and widespread, it can be safely corrected with a variety of supplement types and regimens available and thus should be identified and addressed in the clinical practice of treating diseases associated with it.


Conflict of interest

The authors declare no conflict of interest.


  1. 1. Black LJ, Seamans KM, Cashman KD, Kiely M. An updated systematic review and meta-analysis of the efficacy of vitamin D food fortification. The Journal of nutrition. 2012 Jun 1;142(6):1102-8
  2. 2. Visser M, Deeg DJ, Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. The Journal of Clinical Endocrinology & Metabolism. 2003 Dec 1;88(12):5766-72
  3. 3. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM. The nuclear receptor superfamily: the second decade. Cell. 1995 Dec 15;83(6):835
  4. 4. Poon AH, Gong L, Brasch-Andersen C, Litonjua AA, Raby BA, Hamid Q , Laprise C, Weiss ST, Altman RB, Klein TE. Very important pharmacogene summary for VDR. Pharmacogenetics and genomics. 2012 Oct;22(10):758
  5. 5. Takeyama KI, Masuhiro Y, Fuse H, Endoh H, Murayama A, Kitanaka S, Suzawa M, Yanagisawa J, Kato S. Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog. Molecular and Cellular Biology. 1999 Feb 1;19(2):1049-55
  6. 6. Targher G, Pichiri I, Lippi G. Vitamin D, thrombosis, and hemostasis: more than skin deep. InSeminars in thrombosis and hemostasis 2012 Feb (Vol. 38, No. 01, pp. 114-124). Thieme Medical Publishers
  7. 7. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. The Journal of Clinical Endocrinology & Metabolism. 2011 Jan 1;96(1):53-8
  8. 8. Holick MF. Resurrection of vitamin D deficiency and rickets. The Journal of clinical investigation. 2006 Aug 1;116(8):2062-72
  9. 9. Aaron JE, Stasiak L, Gallagher JC, Longton EB, Nicholson M, Anderson J, Nordin BE. Frequency of osteomalacia and osteoporosis in fractures of the proximal femur. The Lancet. 1974 Feb 16;303(7851):229-33
  10. 10. Khademvatani K, Seyyed-Mohammadzad MH, Akbari M, Rezaei Y, Eskandari R, Rostamzadeh A. The relationship between vitamin D status and idiopathic lower-extremity deep vein thrombosis. International journal of general medicine. 2014;7:303
  11. 11. Wu WX, He DR. Low vitamin D levels are associated with the development of deep venous thromboembolic events in patients with ischemic stroke. Clinical and applied thrombosis/hemostasis. 2018 Dec;24(9_suppl):69S–75S
  12. 12. Koyama T, Hirosawa S. Anticoagulant effects of synthetic retinoids and activated vitamin D3. In Seminars in thrombosis and hemostasis 1998 Jun (Vol. 24, No. 03, pp. 217-226). Copyright© 1998 by Thieme Medical Publishers, Inc
  13. 13. Koyama T, Shibakura M, Ohsawa M, Kamiyama R, Hirosawa S. Anticoagulant effects of 1α, 25-dihydroxyvitamin D3 on human myelogenous leukemia cells and monocytes. Blood, The Journal of the American Society of Hematology. 1998 Jul 1;92(1):160-7
  14. 14. Adorini L. Intervention in autoimmunity: the potential of vitamin D receptor agonists. Cellular immunology. 2005 Feb 1;233(2):115-24
  15. 15. Bhalla AK, Amento EP, Serog B, Glimcher LH. 1, 25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation. The Journal of Immunology. 1984 Oct 1;133(4):1748-54
  16. 16. Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1, 25-dihydroxyvitamin D3 receptors in human leukocytes. Science. 1983 Sep 16;221(4616):1181-3
  17. 17. Brennan A, Katz DR, Nunn JD, Barker S, Hewison M, Fraher LJ, O'Riordan JL. Dendritic cells from human tissues express receptors for the immunoregulatory vitamin D3 metabolite, dihydroxycholecalciferol. Immunology. 1987 Aug;61(4):457
  18. 18. Merke J, Milde P, Lewicka S, Hügel U, Klaus G, Mangelsdorf DJ, Haussler MR, Rauterberg EW, Ritz E. Identification and regulation of 1, 25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1, 25-dihydroxyvitamin D3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. The Journal of clinical investigation. 1989 Jun 1;83(6):1903-15
  19. 19. Esmon CT. Basic mechanisms and pathogenesis of venous thrombosis. Blood reviews. 2009 Sep 1;23(5):225-9
  20. 20. Gupta N, Sahu A, Prabhakar A, Chatterjee T, Tyagi T, Kumari B, Khan N, Nair V, Bajaj N, Sharma M, Ashraf MZ. Activation of NLRP3 inflammasome complex potentiates venous thrombosis in response to hypoxia. Proceedings of the National Academy of Sciences. 2017 May 2;114(18):4763-8
  21. 21. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nature Reviews Immunology. 2013 Jan;13(1):34-45
  22. 22. Ertek S, Akgül E, Cicero AF, Kütük U, Demirtaş S, Çehreli S, Erdoğan G. 25-Hydroxy vitamin D levels and endothelial vasodilator function in normotensive women. Archives of medical science: AMS. 2012 Feb 29;8(1):47
  23. 23. Harris RA, Pedersen-White J, Guo DH, Stallmann-Jorgensen IS, Keeton D, Huang Y, Shah Y, Zhu H, Dong Y. Vitamin D3 supplementation for 16 weeks improves flow-mediated dilation in overweight African-American adults. American journal of hypertension. 2011 May 1;24(5):557-62
  24. 24. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. The American journal of clinical nutrition. 2006 Apr;83(4):754-9
  25. 25. Ohsawa M, Koyama T, Yamamoto K, Hirosawa S, Kamei S, Kamiyama R. 1α, 25-dihydroxyvitamin D3 and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocytic cells, counteracting the effects of tumor necrosis factor and oxidized LDL. Circulation. 2000 Dec 5;102(23):2867-72
  26. 26. Martinez-Moreno JM, Herencia C, Oca AM, Muñoz-Castañeda JR, Rodríguez-Ortiz ME, Díaz-Tocados JM, Peralbo-Santaella E, Camargo A, Canalejo A, Rodriguez M, Velasco-Gimena F. Vitamin D modulates tissue factor and protease-activated receptor 2 expression in vascular smooth muscle cells. The FASEB Journal. 2016 Mar;30(3):1367-76
  27. 27. Toderici M, de la Morena-Barrio ME, Padilla J, Miñano A, Antón AI, Iniesta JA, Herranz MT, Fernández N, Vicente V, Corral J. Identification of regulatory mutations in SERPINC1 affecting vitamin D response elements associated with antithrombin deficiency. Plos one. 2016 Mar 22;11(3):e0152159
  28. 28. Holick MF. Vitamin D deficiency. New England Journal of Medicine. 2007 Jul 19;357(3):266-81
  29. 29. Anderson JL, May HT, Horne BD, Bair TL, Hall NL, Carlquist JF, Lappé DL, Muhlestein JB, Group IH. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. The American journal of cardiology. 2010 Oct 1;106(7):963-8
  30. 30. Vacek JL, Vanga SR, Good M, Lai SM, Lakkireddy D, Howard PA. Vitamin D deficiency and supplementation and relation to cardiovascular health. The American journal of cardiology. 2012 Feb 1;109(3):359-63
  31. 31. Kheiri B, Abdalla A, Osman M, Ahmed S, Hassan M, Bachuwa G. Vitamin D deficiency and risk of cardiovascular diseases: a narrative review. Clinical hypertension. 2018 Dec;24(1):1-9
  32. 32. Lee JH, O'Keefe JH, Bell D, Hensrud DD, Holick MF. Vitamin D deficiency: an important, common, and easily treatable cardiovascular risk factor?. Journal of the American College of Cardiology. 2008 Dec 9;52(24):1949-56
  33. 33. Pilz S, Tomaschitz A, März W, Drechsler C, Ritz E, Zittermann A, Cavalier E, Pieber TR, Lappe JM, Grant WB, Holick MF. Vitamin D, cardiovascular disease and mortality. Clinical endocrinology. 2011 Nov;75(5):575-84
  34. 34. Agmon-Levin N, Blank M, Zandman-Goddard G, Orbach H, Meroni PL, Tincani A, Doria A, Cervera R, Miesbach W, Stojanovich L, Barak V. Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Annals of the Rheumatic Diseases. 2011 Jan 1;70(1):145-50
  35. 35. Beer TM, Venner PM, Ryan CW, Petrylak DP, Chatta G, Dean Ruether J, Chi KN, Curd JG, DeLoughery TG. High dose calcitriol may reduce thrombosis in cancer patients. British journal of haematology. 2006 Nov;135(3):392-4
  36. 36. Koyama T, Hirosawa S. Anticoagulant effects of synthetic retinoids and activated vitamin D3. InSeminars in thrombosis and hemostasis 1998 Jun (Vol. 24, No. 03, pp. 217-226). Copyright© 1998 by Thieme Medical Publishers, Inc
  37. 37. Maillard CH, Berruyer MI, Serre CM, Amiral JE, Dechavanne MA, Delmas PD. Thrombomodulin is synthesized by osteoblasts, stimulated by 1, 25-(OH) 2D3 and activates protein C at their cell membrane. Endocrinology. 1993 Aug 1;133(2):668-74
  38. 38. Michel G, Gailis A, Jarzebska-Deussen B, Muüschen A, Mirmohammadsadegh A, Ruzicka T. 1, 25-(OH) 2-vitamin D 3 and calcipotriol induce IL-10 receptor gene expression in human epidermal cells. Inflammation Research. 1997 Jan;46(1):32-4
  39. 39. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocrine reviews. 2005 Aug 1;26(5):662-87
  40. 40. Koyama T, Hirosawa S. Anticoagulant effects of synthetic retinoids and activated vitamin D3. InSeminars in thrombosis and hemostasis 1998 Jun (Vol. 24, No. 03, pp. 217-226). Copyright© 1998 by Thieme Medical Publishers, Inc
  41. 41. Li YC, Kong J, Wei M, Chen ZF, Liu SQ , Cao LP. 1, 25-Dihydroxyvitamin D 3 is a negative endocrine regulator of the renin-angiotensin system. The Journal of clinical investigation. 2002 Jul 15;110(2):229-38
  42. 42. Sun J, Kong J, Duan Y, Szeto FL, Liao A, Madara JL, Li YC. Increased NF-κB activity in fibroblasts lacking the vitamin D receptor. American Journal of Physiology-Endocrinology and Metabolism. 2006 Aug;291(2):E315-22
  43. 43. Aihara KI, Azuma H, Akaike M, Ikeda Y, Yamashita M, Sudo T, Hayashi H, Yamada Y, Endoh F, Fujimura M, Yoshida T. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. Journal of Biological Chemistry. 2004 Aug 20;279(34):35798-802
  44. 44. Silvagno F, De Vivo E, Attanasio A, Gallo V, Mazzucco G, Pescarmona G. Mitochondrial localization of vitamin D receptor in human platelets and differentiated megakaryocytes. PLoS One. 2010 Jan 13;5(1):e8670
  45. 45. Hyppönen E, Berry D, Cortina-Borja M, Power C. 25-Hydroxyvitamin D and pre-clinical alterations in inflammatory and hemostatic markers: a cross sectional analysis in the 1958 British Birth Cohort. PloS one. 2010 May 24;5(5):e10801
  46. 46. Stewart GJ. Neutrophils and deep venous thrombosis. Pathophysiology of Haemostasis and Thrombosis. 1993;23(Suppl. 1):127-40
  47. 47. Pabinger I, Ay C. Biomarkers and venous thromboembolism. Arteriosclerosis, thrombosis, and vascular biology. 2009 Mar 1;29(3):332-6
  48. 48. Jorde R, Haug E, Figenschau Y, Hansen JB. Serum levels of vitamin D and haemostatic factors in healthy subjects: the Tromsø study. Acta haematologica. 2007;117(2):91-7
  49. 49. Vanhoutte PM. Endothelial dysfunction and atherosclerosis. European heart journal. 1997 Nov 1;18(suppl_E):19-29
  50. 50. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004 Jun 15;109(23_suppl_1):III-27
  51. 51. Schuett H, Luchtefeld M, Grothusen C, Grote K, Schieffer B. How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thrombosis and haemostasis. 2009;102(08):215-22
  52. 52. Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nature Reviews Immunology. 2007 Oct;7(10):803-15
  53. 53. Dejana E, Tournier-Lasserve E, Weinstein BM. The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications. Developmental cell. 2009 Feb 17;16(2):209-21
  54. 54. Hadi HA, Carr CS, Al Suwaidi J. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vascular health and risk management. 2005 Sep;1(3):183
  55. 55. Bombeli T, Mueller M, Haeberli A. Anticoagulant properties of the vascular endothelium. Thrombosis and haemostasis. 1997;77(03):408-23
  56. 56. Nawroth PP, Handley D, Stern DM. The multiple levels of endothelial cell-coagulation factor interactions. Clinics in haematology. 1986 May 1;15(2):293-321
  57. 57. Zehnder D, Bland R, Chana RS, Wheeler DC, Howie AJ, Williams MC, Stewart PM, Hewison M. Synthesis of 1, 25-dihydroxyvitamin D3 by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. Journal of the American Society of Nephrology. 2002 Mar 1;13(3):621-9
  58. 58. Jablonski KL, Chonchol M, Pierce GL, Walker AE, Seals DR. 25-Hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adults. Hypertension. 2011 Jan;57(1):63-9
  59. 59. Mitsuhashi T, Morris RC, Ives HE. 1, 25-dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells. The Journal of clinical investigation. 1991 Jun 1;87(6):1889-95
  60. 60. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE. 1α, 25-dihydroxyvitamin D3 inhibits angiogenesis in vitro and in vivo. Circulation research. 2000 Aug 4;87(3):214-20
  61. 61. Molinari C, Uberti F, Grossini E, Vacca G, Carda S, Invernizzi M, Cisari C. 1α, 25-dihydroxycholecalciferol induces nitric oxide production in cultured endothelial cells. Cellular Physiology and Biochemistry. 2011;27(6):661-8
  62. 62. Andrukhova O, Slavic S, Zeitz U, Riesen SC, Heppelmann MS, Ambrisko TD, Markovic M, Kuebler WM, Erben RG. Vitamin D is a regulator of endothelial nitric oxide synthase and arterial stiffness in mice. Molecular Endocrinology. 2014 Jan 1;28(1):53-64
  63. 63. Tarcin O, Yavuz DG, Ozben B, Telli A, Ogunc AV, Yuksel M, Toprak A, Yazici D, Sancak S, Deyneli O, Akalin S. Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. The Journal of Clinical endocrinology & metabolism. 2009 Oct 1;94(10):4023-30
  64. 64. Kamen DL, Oates J. A pilot randomized, controlled trial of vitamin D repletion to determine if endothelial function improves in patients with systemic lupus erythematosus. The American journal of the medical sciences. 2015 Oct;350(4):302
  65. 65. Carrara D, Bernini M, Bacca A, Rugani I, Duranti E, Virdis A, Ghiadoni L, Taddei S, Bernini G. Cholecalciferol administration blunts the systemic renin–angiotensin system in essential hypertensives with hypovitaminosis D. Journal of the Renin-Angiotensin-Aldosterone System. 2014 Mar;15(1):82-7
  66. 66. Chitalia N, Ismail T, Tooth L, Boa F, Hampson G, Goldsmith D, Kaski JC, Banerjee D. Impact of vitamin D supplementation on arterial vasomotion, stiffness and endothelial biomarkers in chronic kidney disease patients. PloS one. 2014 Mar 19;9(3):e91363
  67. 67. Dong Y, Stallmann-Jorgensen IS, Pollock NK, Harris RA, Keeton D, Huang Y, Li K, Bassali R, Guo DH, Thomas J, Pierce GL. A 16-week randomized clinical trial of 2000 international units daily vitamin D3 supplementation in black youth: 25-hydroxyvitamin D, adiposity, and arterial stiffness. The Journal of Clinical Endocrinology & Metabolism. 2010 Oct 1;95(10):4584-91
  68. 68. Carrara D, Bruno RM, Bacca A, Taddei S, Duranti E, Ghiadoni L, Bernini G. Cholecalciferol treatment downregulates renin–angiotensin system and improves endothelial function in essential hypertensive patients with hypovitaminosid D. Journal of hypertension. 2016 Nov 1;34(11):2199-205
  69. 69. Gibson CC, Davis CT, Zhu W, Bowman-Kirigin JA, Walker AE, Tai Z, Thomas KR, Donato AJ, Lesniewski LA, Li DY. Dietary vitamin D and its metabolites non-genomically stabilize the endothelium. PloS one. 2015 Oct 15;10(10):e0140370
  70. 70. Kanikarla-Marie P, Jain SK. 1, 25 (OH) 2D3 inhibits oxidative stress and monocyte adhesion by mediating the upregulation of GCLC and GSH in endothelial cells treated with acetoacetate (ketosis). The Journal of steroid biochemistry and molecular biology. 2016 May 1;159:94-101
  71. 71. Chen SF. 1 alpha, 25-Dihydroxyvitamin D3 decreased ICAM-1 and ELAM-1 expressions on pulmonary microvascular endothelial cells and neutrophil motivation. The Journal of steroid biochemistry and molecular biology. 1995 Jan 1;52(1):67-70
  72. 72. Rahman A, Fazal F. Blocking NF-κB: an inflammatory issue. Proceedings of the American Thoracic Society. 2011 Nov 1;8(6):497-503
  73. 73. Equils O, Naiki Y, Shapiro AM, Michelsen K, Lu D, Adams J, Jordan S. 1, 25-Dihydroxyvitamin D3 inhibits lipopolysaccharide-induced immune activation in human endothelial cells. Clinical & Experimental Immunology. 2006 Jan;143(1):58-64
  74. 74. Suzuki Y, Ichiyama T, Ohsaki A, Hasegawa S, Shiraishi M, Furukawa S. Anti-inflammatory effect of 1α, 25-dihydroxyvitamin D3 in human coronary arterial endothelial cells: Implication for the treatment of Kawasaki disease. The Journal of steroid biochemistry and molecular biology. 2009 Jan 1;113(1-2):134-8
  75. 75. Xu W, Hu X, Qi X, Zhu R, Li C, Zhu Y, Yin S, Cheng L, Zhu R. Vitamin D ameliorates angiotensin II-induced human endothelial progenitor cell injury via the PPAR-γ/HO-1 pathway. Journal of vascular research. 2019;56(1):17-27
  76. 76. Liang B, Wang X, Zhang N, Yang H, Bai R, Liu M, Bian Y, Xiao C, Yang Z. Angiotensin-(1-7) attenuates angiotensin II-induced ICAM-1, VCAM-1, and MCP-1 expression via the MAS receptor through suppression of P38 and NF-κB pathways in HUVECs. Cellular Physiology and Biochemistry. 2015;35(6):2472-82
  77. 77. Bozic M, Álvarez Á, de Pablo C, Sanchez-Niño MD, Ortiz A, Dolcet X, Encinas M, Fernandez E, Valdivielso JM. Impaired vitamin D signaling in endothelial cell leads to an enhanced leukocyte-endothelium interplay: implications for atherosclerosis development. PLoS One. 2015 Aug 31;10(8):e0136863
  78. 78. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Archives of internal medicine. 2007 Sep 10;167(16):1730-7
  79. 79. Wang L, Manson JE, Song Y, Sesso HD. Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events. Annals of internal medicine. 2010 Mar 2;152(5):315-23
  80. 80. Hashemi SM, Mokhtari SM, Sadeghi M, Foroozan R, Safari M. Effect of vitamin D therapy on endothelial function in ischemic heart disease female patients with vitamin D deficiency or insufficiency: A primary report. ARYA atherosclerosis. 2015 Jan;11(1):54
  81. 81. Hammer Y, Soudry A, Levi A, Talmor-Barkan Y, Leshem-Lev D, Singer J, Kornowski R, Lev EI. Effect of vitamin D on endothelial progenitor cells function. PloS one. 2017 May 17;12(5):e0178057
  82. 82. Vila Cuenca M, Ferrantelli E, Meinster E, Pouw SM, Kovačević I, de Menezes RX, Niessen HW, Beelen RH, Hordijk PL, Vervloet MG. Vitamin D attenuates endothelial dysfunction in uremic rats and maintains human endothelial stability. Journal of the American Heart Association. 2018 Sep 4;7(17):e008776
  83. 83. Kirchhofer D, Tschopp TB, Hadvary P, Baumgartner HR. Endothelial cells stimulated with tumor necrosis factor-alpha express varying amounts of tissue factor resulting in inhomogenous fibrin deposition in a native blood flow system. Effects of thrombin inhibitors. The Journal of clinical investigation. 1994 May 1;93(5):2073-83
  84. 84. Yamamoto K, Shimokawa T, Kojima T, Loskutoff DJ, Saito H. Regulation of murine protein C gene expression in vivo: effects of tumor necrosis factor-α, interleukin-1, and transforming growth factor-β. Thrombosis and haemostasis. 1999;82(10):1297-301
  85. 85. van Hinsbergh VW. Endothelium—role in regulation of coagulation and inflammation. InSeminars in immunopathology 2012 Jan (Vol. 34, No. 1, pp. 93-106). Springer-Verlag
  86. 86. Eilertsen KE, Østerud B. Tissue factor:(patho) physiology and cellular biology. Blood coagulation & fibrinolysis. 2004 Oct 1;15(7):521-38
  87. 87. Darbousset R, Thomas GM, Mezouar S, Frere C, Bonier R, Mackman N, Renné T, Dignat-George F, Dubois C, Panicot-Dubois L. Tissue factor–positive neutrophils bind to injured endothelial wall and initiate thrombus formation. Blood, The Journal of the American Society of Hematology. 2012 Sep 6;120(10):2133-43
  88. 88. Hewison M. An update on vitamin D and human immunity. Clinical endocrinology. 2012 Mar;76(3):315-25
  89. 89. Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health consequences. The American journal of clinical nutrition. 2008 Apr 1;87(4):1080S–6S
  90. 90. Veldman CM, Cantorna MT, DeLuca HF. Expression of 1, 25-dihydroxyvitamin D3 receptor in the immune system. Archives of biochemistry and biophysics. 2000 Feb 15;374(2):334-8
  91. 91. Mahon BD, Wittke A, Weaver V, Cantorna MT. The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. Journal of cellular biochemistry. 2003 Aug 1;89(5):922-32
  92. 92. van Etten E, Mathieu C. Immunoregulation by 1, 25-dihydroxyvitamin D3: basic concepts. The Journal of steroid biochemistry and molecular biology. 2005 Oct 1;97(1-2):93-101
  93. 93. Adams JS, Hewison M. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nature clinical practice Endocrinology & metabolism. 2008 Feb;4(2):80-90
  94. 94. Dutta D, Mondal SA, Choudhuri S, Maisnam I, Reza AH, Bhattacharya B, Chowdhury S, Mukhopadhyay S. Vitamin-D supplementation in prediabetes reduced progression to type 2 diabetes and was associated with decreased insulin resistance and systemic inflammation: an open label randomized prospective study from Eastern India. Diabetes research and clinical practice. 2014 Mar 1;103(3):e18-23
  95. 95. Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-Court D, Aganna E, Price CP, Boucher BJ. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders?. Qjm. 2002 Dec 1;95(12):787-96
  96. 96. Shab-Bidar S, Neyestani TR, Djazayery A, Eshraghian MR, Houshiarrad A, Kalayi A, Shariatzadeh N, Khalaji N, Gharavi AA. Improvement of vitamin D status resulted in amelioration of biomarkers of systemic inflammation in the subjects with type 2 diabetes. Diabetes/metabolism research and reviews. 2012 Jul;28(5):424-30
  97. 97. Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, Kinkeldei J, Boehm BO, Weihrauch G, Maerz W. Independent association of low serum 25-hydroxyvitamin D and 1, 25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Archives of internal medicine. 2008 Jun 23;168(12):1340-9
  98. 98. Ponsonby AL, McMichael A, Van Der Mei I. Ultraviolet radiation and autoimmune disease: insights from epidemiological research. Toxicology. 2002 Dec 27;181:71-8
  99. 99. Staples JA, Ponsonby AL, Lim LL, McMichael AJ. Ecologic analysis of some immune-related disorders, including type 1 diabetes, in Australia: latitude, regional ultraviolet radiation, and disease prevalence. Environmental Health Perspectives. 2003 Apr;111(4):518-23
  100. 100. Boucher BJ. The problems of vitamin d insufficiency in older people. Aging and disease. 2012 Aug;3(4):313
  101. 101. Dudani SJ, Kalhan S, Sharma SP. Vitamin D and multiple sclerosis: Potential pathophysiological role and clinical implications. International Journal of Applied and Basic Medical Research. 2011 Jul;1(2):71
  102. 102. Akbas EM, Gungor A, Ozcicek A, Akbas N, Askin S, Polat M. Vitamin D and inflammation: evaluation with neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio. Archives of medical science: AMS. 2016 Aug 1;12(4):721
  103. 103. Amer M, Qayyum R. Relation between serum 25-hydroxyvitamin D and C-reactive protein in asymptomatic adults (from the continuous National Health and Nutrition Examination Survey 2001 to 2006). The American journal of cardiology. 2012 Jan 15;109(2):226-30
  104. 104. Laird E, McNulty H, Ward M, Hoey L, McSorley E, Wallace JM, Carson E, Molloy AM, Healy M, Casey MC, Cunningham C. Vitamin D deficiency is associated with inflammation in older Irish adults. The Journal of Clinical Endocrinology & Metabolism. 2014 May 1;99(5):1807-15
  105. 105. Bellia A, Garcovich C, D’Adamo M, Lombardo M, Tesauro M, Donadel G, Gentileschi P, Lauro D, Federici M, Lauro R, Sbraccia P. Serum 25-hydroxyvitamin D levels are inversely associated with systemic inflammation in severe obese subjects. Internal and emergency medicine. 2013 Feb;8(1):33-40
  106. 106. Jorde R, Sneve M, Torjesen PA, Figenschau Y, Gøransson LG, Omdal R. No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects. Cytokine. 2010 May 1;50(2):175-80
  107. 107. Ward KA, Das G, Roberts SA, Berry JL, Adams JE, Rawer R, Mughal MZ. A randomized, controlled trial of vitamin D supplementation upon musculoskeletal health in postmenarchal females. The Journal of Clinical Endocrinology & Metabolism. 2010 Oct 1;95(10):4643-51
  108. 108. Holick MF. Vitamin D: photobiology, metabolism of action, and clinical applications. Primer on the Metabolic Bone Diseases. 1999
  109. 109. Feldman D, Malloy PJ, Gross C. Vitamin D: biology, action, and clinical implications. InOsteoporosis 2001 Jan 1 (pp. 257-303). Academic Press
  110. 110. DeLuca HF. Overview of general physiologic features and functions of vitamin D. The American journal of clinical nutrition. 2004 Dec 1;80(6):1689S–96S
  111. 111. Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Luderer HF, Lieben L, Mathieu C, Demay M. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocrine reviews. 2008 Oct 1;29(6):726-76
  112. 112. Mussolino ME, Gillum RF. Low bone mineral density and mortality in men and women: the Third National Health and Nutrition Examination Survey linked mortality file. Annals of epidemiology. 2008 Nov 1;18(11):847-50
  113. 113. Suzuki T, Yoshida H. Low bone mineral density at femoral neck is a predictor of increased mortality in elderly Japanese women. Osteoporosis international. 2010 Jan;21(1):71-9
  114. 114. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. Jama. 2005 May 11;293(18):2257-64
  115. 115. Nieves J, Cosman F, Herbert J, Shen V, Lindsay R. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology. 1994 Sep 1;44(9):1687-
  116. 116. Plotnikoff GA, Quigley JM. Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. InMayo clinic proceedings 2003 Dec 1 (Vol. 78, No. 12, pp. 1463-1470). Elsevier
  117. 117. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. The American journal of clinical nutrition. 2006 Jun 1;84(1):18-28
  118. 118. Broe KE, Chen TC, Weinberg J, Bischoff-Ferrari HA, Holick MF, Kiel DP. A higher dose of vitamin D reduces the risk of falls in nursing home residents: a randomized, multiple-dose study. Journal of the American Geriatrics Society. 2007 Feb;55(2):234-9
  119. 119. Carthy EP, Yamashita W, Hsu A, Ooi BS. 1, 25-Dihydroxyvitamin D3 and rat vascular smooth muscle cell growth. Hypertension. 1989 Jun;13(6_pt_2):954-9
  120. 120. Michos ED, Melamed ML. Vitamin D and cardiovascular disease risk. Current Opinion in Clinical Nutrition & Metabolic Care. 2008 Jan 1;11(1):7-12
  121. 121. Kuneš J, Tremblay J, Bellavance F, Hamet P. Influence of environmental temperature on the blood pressure of hypertensive patients in Montreal. American journal of hypertension. 1991 May 1;4(5_Pt_1):422-6
  122. 122. Krause R, Bühring M, Hopfenmüller W, Holick MF, Sharma AM. Ultraviolet B and blood pressure. Lancet (British edition). 1998;352(9129):709-10
  123. 123. McAlpine D, Compston A. McAlpine's multiple sclerosis. Elsevier Health Sciences; 2005
  124. 124. Gale CR, Martyn CN. Migrant studies in multiple sclerosis. Progress in neurobiology. 1995 Nov 1;47(4-5):425-48
  125. 125. Acheson ED, Bachrach CA, Wright FM. Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation, and other variables. Acta Psychiatrica Scandinavica. 1960 Nov;35(S147):132-47
  126. 126. Norman Jr JE, Kurtzke JF, Beebe GW. Epidemiology of multiple sclerosis in US veterans: 2. Latitude, climate and the risk of multiple sclerosis. Journal of chronic diseases. 1983 Jan 1;36(8):551-9
  127. 127. Goldberg P. Multiple sclerosis: vitamin D and calcium as environmental determinants of prevalence: (A viewpoint) part 2. biochemical and genetic factors. International Journal of Environmental Studies. 1974 Jan 1;6(2-3):121-9
  128. 128. Acheson ED, Bachrach CA, Wright FM. Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation, and other variables. Acta Psychiatrica Scandinavica. 1960 Nov;35(S147):132-47
  129. 129. Sutherland JM, Tyrer JH, Eadie MJ. The prevalence of multiple sclerosis in Australia. Brain. 1962 Mar 1;85(1):149-64
  130. 130. VanAmerongen BM, Dijkstra CD, Lips P, Polman CH. Multiple sclerosis and vitamin D: an update. European journal of clinical nutrition. 2004 Aug;58(8):1095-109
  131. 131. Pierrot-Deseilligny C, Souberbielle JC. Vitamin D and multiple sclerosis: an update. Multiple sclerosis and related disorders. 2017 May 1;14:35-45
  132. 132. Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. The Lancet Neurology. 2010 Jun 1;9(6):599-612
  133. 133. Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer?. International journal of epidemiology. 1980 Sep 1;9(3):227-31
  134. 134. Garland FC, Garland CF, Gorham ED, Young JF. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Preventive medicine. 1990 Nov 1;19(6):614-22
  135. 135. LEFKOWITZ ES, Garland CF. Sunlight, vitamin D, and ovarian cancer mortality rates in US women. International journal of epidemiology. 1994 Dec 1;23(6):1133-6
  136. 136. Young MR, Halpin J, Hussain R, Lozano Y, Djordjevic A, Devata S, Matthews JP, Wright MA. Inhibition of tumor production of granulocyte-macrophage colony-stimulating factor by 1 alpha, 25-dihydroxyvitamin D3 reduces tumor motility and metastasis. Invasion & metastasis. 1993 Jan 1;13(4):169-77
  137. 137. Evans SR, Shchepotin EI, Young HE, Rochon JA, Uskokovic MI, Shchepotin IB. 1, 25-dihydroxyvitamin D3 synthetic analogs inhibit spontaneous metastases in a 1, 2-dimethylhydrazine-induced colon carcinogenesis model. International journal of oncology. 2000 Jun 1;16(6):1249-303
  138. 138. FUJIOKA T, HASEGAWA M, ISHIKURA K, MATSUSHITA Y, SATO M, TANJI S. Inhibition of tumor growth and angiogenesis by vitamin D3 agents in murine renal cell carcinoma. The Journal of urology. 1998 Jul;160(1):247-51. Sundaram S, Sea A, Feldman S, Strawbridge R, Hoopes PJ, Demidenko E, Binderup L, Gewirtz DA. The combination of a potent vitamin D3 analog, EB 1089, with ionizing radiation reduces tumor growth and induces apoptosis of MCF-7 breast tumor xenografts in nude mice. Clinical Cancer Research. 2003 Jun 1;9(6):2350-6
  139. 139. Holick MF. Vitamin D: its role in cancer prevention and treatment. Progress in biophysics and molecular biology. 2006 Sep 1;92(1):49-59
  140. 140. Feskanich D, Ma J, Fuchs CS, Kirkner GJ, Hankinson SE, Hollis BW, Giovannucci EL. Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiology and Prevention Biomarkers. 2004 Sep 1;13(9):1502-8
  141. 141. John EM, Schwartz GG, Dreon DM, Koo J. Vitamin D and breast cancer risk: the NHANES I epidemiologic follow-up study, 1971-1975 to 1992. Cancer Epidemiology and Prevention Biomarkers. 1999 May 1;8(5):399-406
  142. 142. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes care. 2004 May 1;27(5):1047-53
  143. 143. Martineau AR, Honecker FU, Wilkinson RJ, Griffiths CJ. Vitamin D in the treatment of pulmonary tuberculosis. The Journal of steroid biochemistry and molecular biology. 2007 Mar 1;103(3-5):793-8
  144. 144. Blondon M, Rodabough RJ, Budrys N, Johnson KC, Berger JS, Shikany JM, Raiesdana A, Heckbert SR, Manson JE, LaCroix AZ, Siscovick D. The Effect of Calcium plus vitamin D supplementation on the risk of venous thromboembolism in the Women’s Health Initiative Randomized Controlled Trial. Thrombosis and haemostasis. 2015 May;113(5):999
  145. 145. Moscarelli L, Zanazzi M, Bertoni E, Caroti L, Rosso G, Farsetti S, Annunziata F, Paudice N, Salvadori M. Renin angiotensin system blockade and activated vitamin D as a means of preventing deep vein thrombosis in renal transplant recipients. Clinical nephrology. 2011 May 1;75(5):440-50
  146. 146. Lindqvist PG, Epstein E, Olsson H. Does an active sun exposure habit lower the risk of venous thrombotic events? AD-lightful hypothesis. Journal of Thrombosis and Haemostasis. 2009 Apr;7(4):605-10
  147. 147. Brot C, Vestergaard P, Kolthoff N, Gram J, Hermann AP, Sørensen OH. Vitamin D status and its adequacy in healthy Danish perimenopausal women: relationships to dietary intake, sun exposure and serum parathyroid hormone. British Journal of Nutrition. 2001 Aug;86(S1):S97-103
  148. 148. Bilezikian JP, Bikle D, Hewison M, Lazaretti-Castro M, Formenti AM, Gupta A, Madhavan MV, Nair N, Babalyan V, Hutchings N, Napoli N. Mechanisms in endocrinology: vitamin D and COVID-19. European journal of endocrinology. 2020 Nov 1;183(5):R133-47
  149. 149. Lau FH, Majumder R, Torabi R, Saeg F, Hoffman R, Cirillo JD, Greiffenstein P. Vitamin D insufficiency is prevalent in severe COVID-19. MedRxiv. 2020 Jan 1
  150. 150. Lanham-New SA, Webb AR, Cashman KD, Buttriss JL, Fallowfield JL, Masud T, Hewison M, Mathers JC, Kiely M, Welch AA, Ward KA. Vitamin D and SARS-CoV-2 virus/COVID-19 disease. BMJ Nutrition, Prevention & Health. 2020;3(1):106
  151. 151. Aslan MT, Aslan İÖ, Özdemir Ö. Letter to the Editor: Is Vitamin D One of the Key Elements in COVID-19 Days? J Nutr Health Aging. 2020;24(9):1038-1039. doi: 10.1007/s12603-020-1413-5. PMID: 33155635; PMCID: PMC7597430

Written By

Syed Mohd, Swati Sharma, Aastha Mishra and Mohammad Zahid Ashraf

Submitted: December 11th, 2020 Reviewed: March 17th, 2021 Published: April 29th, 2021